V ery elderly patients (defined as those age 85 years or older) account for approximately 20% of the 3.3 million people treated for nonmelanoma skin cancer (NMSC) each year in the United States. [1] [2] [3] [4] The population age 85 years and older is projected to increase from 5,887,000 in 2012 to 17,978,000 in 2050. 5 Given the predilection for NMSC to develop in the older population because of cumulative sun exposure, the incidence of NMSC is also expected to increase.
NMSCs, most frequently basal cell carcinoma and squamous cell carcinoma, are rarely fatal, but without treatment they may grow over time and become symptomatic. [6] [7] [8] However, some have suggested that the population of very elderly individuals may not live long enough to benefit from treatment. [9] [10] [11] [12] Defining limited life expectancy (LLE) in this population presents 2 challenges: First, what should be considered LLE in an elderly person presenting with NMSC? Various estimates of life expectancy from less than 1 year to less than 5 years have been associated with this term, but there is no consensus among the dermatologic community. As the natural history of untreated basal cell carcinoma and low-risk squamous cell carcinoma have not been well studied, clinicians cannot always predict which tumors will behave indolently and which will progress to cause problems for the patient. Second, although calculators and algorithms exist to better define life expectancy, the select population being referred and considered for treatment of NMSC may perform differently than other populations. To help guide management decisions in this population, a shared decision-making approach, which includes the assessment of comorbidities, has been proposed. 9 The Adult Comorbidity Evaluation-27 (ACE-27) and the age-adjusted Charlson comorbidity index (ACCI) are 2 validated indices used to predict survival in diverse cancer populations, including the populations with head and neck cancer and skin cancer. [13] [14] [15] However, guidelines for use of the ACE-27 and the ACCI for predicting LLE have not been established in very elderly individuals presenting for skin cancer.
To guide the shared decision-making approach in very elderly individuals with NMSC, and for researchers studying this topic, this study was undertaken with the following objective: identify an ACCI and ACE-27 score that identifies patients age 85 years or older presenting for management of NMSC with LLE. For the purposes of this study, a conservative estimate of LLE was defined as less than 50% expected survival in 4 years.
METHODS

Patient selection
This was a single-center retrospective study of prospectively collected patients age 85 years or older who underwent Mohs micrographic surgery (MMS) for NMSC with 3 surgeons in a dermatologic surgery service between July 1999 and December 2014. A retrospective search using an institutional database was performed to identify patients who presented to the service with NMSC and did not undergo MMS during that time period. Patient demographics, tumor characteristics, and surgical details were recorded following chart review. Tumor anatomic risk was defined by using the National Comprehensive Cancer Network guidelines. 16 For those patients who did not have MMS, the reason for treatment choice was noted.
Comorbidity assessment
Electronic medical records were reviewed and comorbidities were scored by using the ACE-27 and the ACCI. Comorbidities recorded in the consultation note were considered if diagnosed on or before the date of consultation. For the ACE-27, a total of 27 comorbidities were assessed by the following scale: grade 0, no disease; grade 1, mild decompensation; grade 2, moderate decompensation; and grade 3, severe decompensation. An overall comorbidity grade between 0 and 3 was determined. For the ACCI, a score was calculated on the basis of age at date of surgery and presence or absence of 19 conditions, which are each assigned a different point value between 1 and 6. To age-adjust for each decade over age 40, an additional point was added to the score. Therefore, our population of patients age 85 and older had 4 or 5 points added to the original CCI score for age.
Follow-up and survival
An institutional database search was conducted to collect last follow-up with a dermatologist, last follow-up at Memorial Sloan Kettering Cancer Center, and date of death. For patients who had MMS, time began at date of surgery. For patients who did not elect to have MMS, time began with the date of MMS consultation. Elapsed time was calculated until death or last follow-up. Participants were considered censored if they were alive or lost to follow-up at the date of last assessment. Alpha was set at 5%, and all analyses were 2 tailed. Analyses were performed with StataSE software (version 14. Patient characteristics were summarized by procedure status (MMS vs no MMS). The Student t tests and chi-square test were used to assess differences in the distribution of patient characteristics, surgical procedure characteristics, and patient comorbidity scores for continuously and categorically scaled variables. For univariate assessments of overall survival, Kaplan-Meier survival curves stratified by MMS status were created. Log-rank tests were used to assess the equality of the unadjusted survivor functions. In addition, Cox proportional hazards regression was used for the analysis of overall survival time.
RESULTS
Patient and lesion characteristics
In all, 488 patients age 85 years or older were included in the study. Of these, 371 of 10,103 total patients who presented for MMS were age 85 years or older. An additional 117 patients age 85 years or older were seen for MMS consultation but did not pursue MMS. Characteristics of the study participants and the presenting skin cancer are presented in Table I . 17, 18 The mean age was 88.1 years and the majority were female (52.5%). The majority of lesions were located on the head and neck (the nose in 19.7% of cases, the scalp in 8.6%, the ear in 5.1%, the periocular area in 4.5%, the lip in 3.5%, the neck in 2.1%, and another part of the face in 30.1%), followed by the extremities (16.6%) and the trunk (6.4%).
Comorbidity
As listed in Table II , the most frequent comorbidities according to the ACE-27 were hypertension (72.7%), followed by solid tumor malignancy (56.1%) and coronary artery disease (22.1%). The mean ACE-27 score was 1.47 and the mean ACCI score was 6.1. Patients who were seen for consultation but did not undergo MMS had mean ACE-27 and ACCI scores similar to those of patients who underwent MMS (1.47 vs 1.47 [P = .64] and 6.2 vs 6.1 [P = .60]).
Survival
The patient cohort was followed for a total of 1631 person-years. During the follow-up period, 230 patients (47%) died, with a mean age of death of 93.5 years; 54 patients (46%) in the non-MMS group died, as did 176 patients (47%) in the MMS group. The Kaplan-Meier survival curves for patients with MMS and without MMS are presented in Fig 1. Patients who underwent MMS had a median survival of 67 months compared with 47 months for patients without MMS [P = .004]. Both ACCI and the ACE-27 scores were significantly associated with overall survival. Because ACCI and ACE-27 scores were highly correlated, separate Cox proportional hazard models were created.
After control for age, sex, anatomic site of tumor on the basis of risk for recurrence, and comorbidities as assessed with the ACCI, the patients in the MMS group had significantly better survival than those in the non-MMS group (hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.46-0.86). Similar results were observed for the Cox model substituting ACE-27 scores for ACCI (HR, 0.59; 95% CI, 0.43-0.81). Higher ACCI and ACE-27 scores were both significantly associated with poorer survival. Each 1-point increase in ACCI score was associated with a 16% increase in mortality (HR, 1.16; 95% CI,1.09-1.24), whereas each 1-point increase in ACE-27 was associated with a 21% increase in mortality (HR, 1.21; 95% CI, 1.13-1.30). The Cox models were assessed and met the assumption of proportionality. Hazard estimates for death on the basis of their overall ACE-27 and ACCI scores are presented in Figs 2 and 3.
DISCUSSION
Life expectancy is estimated to increase from 6 to 7 years in men and from 7.1 to 8.5 years in women age 85 years between 2012 and 2050. 5 With life expectancy and the proportion of the population of very elderly individuals projected to increase in the United States, the management of nonelife-threatening illnesses such as skin cancer will increasingly be relevant. In this study, patients presenting to a tertiary cancer center for MMS had a mean age of death of 93.5 years and longer than the predicted national life expectancies of 76.4 years for males and 81.2 years for females. 19 This elderly group presenting for NMSC evaluation may be in better overall health than the general population. If patients are severely decompensated or managing several active comorbidities, prioritization of their health conditions may lead to skin cancer treatment being deferred.
Although the definition of LLE varies, less than 50% survival at 4 years was seen in those patients with an ACE-27 score of 3 or ACCI score of 71. Age and comorbidity status were strikingly similar between patients undergoing MMS and patients not undergoing MMS, but patients who underwent MMS survived a median of 20 months longer. These results suggest that selection bias or a confounding factor such as high functional status was protective for those patients presenting for specialized surgical management. Functional status is evaluated by assessing activities of daily living in terms of selfcare, communication, and mobility. 20 It is often used as a measure of overall health, can be predictive of survival in older adults, and is independent of comorbidity status. 21, 22 Regula et al previously showed that patients 75 years and older who underwent MMS were generally high functioning. 23 Although functional status was not systematically collected in this population, the patient's overall ability to perform activities of daily living is informally assessed during the preoperative consultation. Patients may also have self-selected on the basis of their own perceived ability to perform wound care, tolerate surgery, and return for follow-up appointments.
The ACCI and ACE-27 were previously identified as the most commonly used formal comorbidity indices in the NMSC population. 15 Our findings indicate that although comorbidity status alone does not explain the survival difference between the cohorts, it was predictive of overall survival. Previous studies have found conflicting results regarding comorbidity status and life expectancy in very elderly individuals. 24, 25 Additionally, the ACCI and the ACE-27 were shown to be similarly useful tools in determining LLE 26 despite differences between the indices. Patients with the highest comorbidity grades had a median survival of less than 4 years compared with 7.2 years for those with the fewest comorbidities.
Linos and et al 10 previously examined patient characteristics in those treated for NMSC and compared participants with and without LLE (the definition included age 85 and older and/or noneage-adjusted CCI score of 3 or higher) in individuals age 65 or older. Their findings demonstrated no difference in rates of treatment modality used between these 2 groups, including the use of MMS. In this study, patients presented for MMS predominantly with facial lesions, and the majority required only 1 or 2 stages for negative margins. Most of the surgical wounds healed by secondary intention or primary closure, illustrating that the simplest and lowest-risk healing approaches were used in this population. These results support prior studies showing that the population age 85 years and older presenting for NMSC management is generally healthy and tolerates MMS. 24, 27, 28 Although various estimations of life expectancy should be components of shared decision making for NMSC interventions, the survival difference observed between the MMS and non-MMS groups despite similar comorbidity scores in this study suggests that a broader view of LLE in this population should be evaluated and further studied.
There are limitations to this study, including its retrospective, observational design. This patient population was also specific to a cancer center and may have a predilection for a different comorbidity profile than those at other medical centers. Nearly half of the patients in both cohorts had a solid organ malignancy or lymphoma, whereas only 10% had diabetes. Furthermore, patients were prescreened by their referring dermatologist. Therefore, there was implicit referral bias that may have affected the improved comorbidity status and life expectancy seen in both cohorts compared with in the general population. 
CONCLUSIONS
Patients 85 years and older presenting to a dermatologic surgery service surpassed expected survival. Higher comorbidity scores were associated with decreased survival, and both the ACE-27 and ACCI were predictive of LLE at scores of 3 and 71, respectively. Patients who underwent MMS survived longer despite similarities in comorbidity profiles between groups, implying that additional factors selected for by patients and their physicians may significantly contribute to survival in this cohort. Age alone is inadequate for making NMSC treatment decisions in very elderly individuals, and a comprehensive approach to management that considers comorbidity, functional status, and anticipated life expectancy should be considered.
